Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

TScan Therapeutics (TCRX) Non-cash Items (2020 - 2025)

TScan Therapeutics (TCRX) has disclosed Non-cash Items for 6 consecutive years, with $7.5 million as the latest value for Q4 2025.

  • Quarterly Non-cash Items rose 91.01% to $7.5 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $7.5 million through Dec 2025, up 91.01% year-over-year, with the annual reading at $7.5 million for FY2025, 115.72% up from the prior year.
  • Non-cash Items for Q4 2025 was $7.5 million at TScan Therapeutics, up from $3.9 million in the prior quarter.
  • The five-year high for Non-cash Items was $28.3 million in Q4 2023, with the low at $1.6 million in Q4 2022.
  • Average Non-cash Items over 5 years is $8.6 million, with a median of $6.6 million recorded in 2021.
  • The sharpest move saw Non-cash Items surged 1723.89% in 2023, then plummeted 86.17% in 2024.
  • Over 5 years, Non-cash Items stood at $2.1 million in 2021, then decreased by 26.87% to $1.6 million in 2022, then soared by 1723.89% to $28.3 million in 2023, then tumbled by 86.17% to $3.9 million in 2024, then soared by 91.01% to $7.5 million in 2025.
  • According to Business Quant data, Non-cash Items over the past three periods came in at $7.5 million, $3.9 million, and $28.3 million for Q4 2025, Q4 2024, and Q4 2023 respectively.